Emcure Pharmaceuticals Key Ratios

Stock Card

NSE: EMCURE | BSE: 544210

₹1,944.60

₹1.60 (0.08%)

As on 01-Oct-2026IST

Market cap

₹36,872 Cr

Revenue (TTM)

₹9,683 Cr

P/E Ratio

36.5

P/B Ratio

Div. Yield

0.2 %

Key Ratios and Highlights

Growth Score (%)	Quarterly		Annual (TTM)
Particulars	QoQ	YoY	1-Year	3-Years	5-Years
Revenue	4.48	22.85	18.36	15.42	8.73
EBIT	13.32	33.30	30.43	13.05	7.93
Net Profit	24.54	40.36	36.84	18.77	17.59
EPS	20.72	41.92	35.74	18.34	17.59
Book Value	--	--	11.30	23.74	15.81

Key Ratios (%)	Average		Annual (TTM)
Particulars	3-Years	5-Years	TTM	Mar-26	Mar-25
EBIT-Margin	10.22	15.18	15.68	14.46	13.74
Net Margin	8.21	9.60	10.47	10.08	8.88
Return on equity	14.43	23.43	21.30	20.09	19.19
Return on Capital	16.79	23.23	--	25.25	22.49
Return on Assets	7.19	9.43	11.42	10.70	8.94
Debt to Equity (x)	--	--	0.05	0.24	0.17

Profitability

View Detailed Peer Comparison

ROCE

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	--	25.25	22.49	19.87	21.97	26.56
Peer Median	--	14.03	16.46	15.49	17.37	17.62

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROE

21.30

Higher than Peers by 11.36

Profit after tax / Average Net worth * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	21.30	20.09	19.19	19.45	25.21	33.19
Peer Median	9.94	13.45	13.87	14.72	15.70	18.36

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROA

11.42

Higher than Peers by 3.88

Profit after tax / Average Total assets * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	11.42	10.70	8.94	7.39	8.97	11.15
Peer Median	7.54	7.94	8.04	7.19	9.43	9.43

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Margin

15.68

Higher than Peers by 6.35

Operating profit (EBIT) / Net Sales * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	15.68	14.46	13.74	13.78	15.39	18.53
Peer Median	9.34	21.31	10.05	10.28	13.90	17.27

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Margin

10.47

Higher than Peers by 1.12

Net profit / Total Income (Net sales plus other income) * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	10.47	10.08	8.88	7.86	9.31	11.87
Peer Median	9.35	11.88	9.11	6.78	10.91	12.99

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Profit Margin

(Net profit + Depreciation) / Gross Sales * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	--	14.44	13.61	12.38	13.48	15.84
Peer Median	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

18.36

Higher than Peers by 11.98

Year on year growth in net sales

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	18.36	16.56	18.59	11.23	2.23	-3.32
Peer Median	6.38	15.92	7.17	10.56	12.63	15.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Growth

30.43

Higher than Peers by 31.46

Year on year growth in operating profit (EBIT)

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	30.43	22.68	18.25	-0.41	-15.11	19.41
Peer Median	-1.03	24.76	12.05	6.17	-2.90	51.73

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Profit Growth

36.84

Higher than Peers by 27.80

Year on year growth in profit after tax

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	36.84	33.05	34.10	-6.10	-20.03	67.84
Peer Median	9.04	24.25	22.15	27.97	-14.10	44.15

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EPS Growth

35.74

Higher than Peers by 33.68

Year on year growth in earnings per share

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	35.74	35.59	30.75	-6.52	-19.66	68.87
Peer Median	2.05	26.11	8.80	--	-3.68	38.52

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Book Value Growth

Year on year growth in book value per share

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	--	11.36	50.94	18.16	26.10	-12.81
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.05

Higher than Peers by 0.03

Total debt / Net worth

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	0.05	0.24	0.17	0.71	0.88	1.05
Peer Median	0.02	0.17	0.03	0.05	0.14	0.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Short term debt to equity ratio

(Short term borrowings / Net worth)

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	--	0.16	0.11	0.32	0.45	0.55
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Current Ratio

1.43

Lower than Peers by 1.09

Current Assets / Current Liabilities and Provisions

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	1.43	1.43	1.71	1.33	1.27	1.15
Peer Median	2.53	2.23	2.20	1.93	1.82	1.75

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Quick Ratio

0.82

Lower than Peers by 0.96

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	0.82	0.82	0.98	0.85	0.81	0.67
Peer Median	1.78	1.82	1.72	1.59	1.30	1.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Interest Coverage

10.36

Higher than Peers by 0.14

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	10.36	9.96	6.53	4.07	4.50	6.53
Peer Median	10.23	11.31	12.28	12.45	16.98	15.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

26.46

Lower than Peers by 0.11

Debtors outstanding / Net Sales * 100

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	26.46	27.84	25.36	27.92	27.54	22.35
Peer Median	26.57	30.82	26.23	23.97	24.57	20.26

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Asset Turnover

1.09

Higher than Peers by 0.41

Sales / Average Total Assets

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	1.09	1.07	1.01	0.95	0.97	0.95
Peer Median	0.67	0.72	0.74	0.88	0.82	0.79

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Receivable days

Average Debtors / Sales * 365

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	--	88.68	87.83	94.32	88.49	84.97
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Inventory Days

Average Inventory / Sales * 365

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	--	84.11	78.64	78.21	84.77	90.46
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Payable days

Average Creditors / Cost of goods sold * 365

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	--	176.65	174.97	193.72	194.85	188.82
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Conversion Cycle

Receivable Days + Inventory Days - Payable Days

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	--	-3.86	-8.50	-21.19	-21.59	-13.39
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

36.46

Lower than Peers by 18.95

Current share price divided by earning per share in the last twelve months

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	36.46	32.73	29.84	--	--	--
Peer Median	55.41	57.68	39.17	40.74	25.97	33.71

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Price / Book Value

7.05

Higher than Peers by 2.30

Current share price divided by book value per share in the latest financial year

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	7.05	6.13	4.58	--	--	--
Peer Median	4.74	4.99	3.61	3.87	2.79	4.36

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Dividend Yield

0.19

Higher than Peers by 0.06

Dividend per share in the past twelve months divided by current share price

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	0.19	0.23	0.28	--	--	--
Peer Median	0.13	0.11	0.19	0.20	0.65	0.28

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EV/EBITDA

19.05

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	19.05	16.68	13.55	1.57	1.55	1.40
Peer Median	--	46.62	28.79	25.41	15.07	23.32

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Market Cap

36,872

Higher than Peers by 30,724

Current Share price multiplied by latest total number of shares outstanding

Company Name	TTM	Mar-26	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18	Mar-17
Emcure Pharmaceuticals	36,872	30,258	20,327	--	--	--
Peer Median	6,148	6,180	3,944	2,959	3,742	6,050

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.